title: FPR2/ALXR agonists and the resolution of inflammation.
abstract: The resolution of inflammation (RoI), once believed to be a passive process, has lately been shown to be an active and delicately orchestrated process. During the resolution phase of acute inflammation, novel mediators, including lipoxins and resolvins, which are members of the specialized pro-resolving mediators of inflammation, are produced. FPR2/ALXR, a receptor modulated by some of these lipids as well as by peptides (e.g., annexin A1), has been shown to be one of the receptors involved in the RoI. The aim of this perspective is to present the concept of the RoI from a medicinal chemistry point of view and to highlight the effort of the research community to discover and develop anti-inflammatory/pro-resolution small molecules to orchestrate inflammation by activation of FPR2/ALXR.
authors.affiliation: Actelion Pharmaceuticals Ltd. , Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
authors.forename: Olivier
authors.initials: O
authors.lastname: Corminboeuf
authors.forename: Xavier
authors.initials: X
authors.lastname: Leroy
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D044042:Receptors, Formyl Peptide / Q000819:agonists*; D044067:Receptors, Lipoxin / Q000819:agonists*
chemical_list: D000893:Anti-Inflammatory Agents; C105101:FPR2 protein, human; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin